Author

Yingyong Xu

Observed names: Ying-Yong Xu, Ying-yong Xu

Observed institutions: Shanghai Jiao Tong University, University of Manchester, Shanghai Children's Medical Center, Celgene (United States)

OpenAlex ID: A5113763254

An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis

2025 · Xiaobing Wang, Yi Zhang, et al. · Cell · 83

Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma

2019 · Grzegorz S. Nowakowski, Annalisa Chiappella, et al. · Haematologica · 24

Cancer research and innovation: conceptualising a persistent anomaly

2023 · Yingyong Xu, Dimitri Gagliardi · Innovation · 3

Current Status and Challenges of Gene Therapy Products

2021 · Yingyong Xu · Zhongguo shengwu gongcheng zazhi · 1

Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST).

2018 · Grzegorz S. Nowakowski, Annalisa Chiappella, et al. · Journal of Clinical Oncology · 1

Review of: "When Costs Eclipse Cure: Does Financial Toxicity Erode Survival Gains from Novel Cancer Therapies?"

2025 · Yingyong Xu

Cytokine receptor armored CAR-T cells enable robust T cell expansion and function in the absence of lymphodepletion

2025 · lina zhou, Jiapan Hu, et al. · Blood

[Analysis of clinical outcomes of 63 children with acute monocytic leukemia].

2011 · Ying-Yong Xu, Jing Chen, et al. · PubMed

[Research advance in allogeneic hematopoietic stem cell transplantation in children with refractory leukemia].

2010 · Ying-yong Xu, Jing Chen · PubMed

Works count: 9

Citation count: 112

H-index: 3

I10-index: 2